Navigation Links
Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing
Date:7/21/2009

NEWARK, Calif., July 21 /PRNewswire/ -- Novasys Medical, Inc., developer of the Renessa(R) treatment for female stress urinary incontinence, announced today that it has received $18.95 million in the second tranche of its previously announced Series D preferred stock financing. The Company received the first tranche of the Series D round in May 2008, with lead investor Versant Ventures and new investors ThreeArch Partners and Skyline Ventures. All three participated in the second tranche, with existing investors Alloy Ventures, Delphi Ventures, GBS Venture Partners and Hercules Technology Growth Capital.

"In this challenging financing environment, we greatly value the continued support of our investors. They understand the tremendous opportunity the non-surgical Renessa treatment offers women," said Debra Reisenthel, President and CEO of Novasys Medical. "This financing will speed the process of securing reimbursement for the Renessa treatment. Since the first tranche of the Series D financing closed last May, we've enjoyed major progress with several key payers agreeing to cover the procedure. These payers include Aetna, plus regional Medicare carriers Noridian , First Coast and TrailBlazers, who cover 27 million lives. Additional payers are expected to join them in covering Renessa soon."

Beckie Robertson, Managing Director with Versant Ventures, said, "We're really pleased with the reimbursement progress Novasys has made with payers in the past year. We're confident this is a huge opportunity in an underserved market."

Female Stress Urinary Incontinence (SUI)

SUI is the involuntary leakage of urine associated with coughing, sneezing, laughing and recreational activities. It is caused by a variety of factors---most commonly childbirth---and often restricts the social, professional, and personal lives of an estimated 15 million women in the U.S. alone. With currently available surgical and non-surgical SUI therapies, many patients and physicians have concerns about safety, recovery, compliance and/or effectiveness. Experts estimate 80% of women with SUI thus do not seek treatment of any kind.

The FDA-cleared Renessa System includes a small probe which a physician passes through the natural opening of the urethra (transurethral). The probe gently heats the tissue in the bladder neck and upper urethra. The heat denatures the collagen in the tissue, and upon healing, the tissue becomes firmer and more resistant to leaks. The Renessa treatment can be performed in the convenience of a physician's office, or in an outpatient setting, using local anesthesia. There are no incisions, bandages or dressings required. Recovery is rapid and comfortable, with minimal post-procedure limitations. More than 350 urologists, urogynecologists and gynecologists have been trained and have performed the Renessa procedure in nearly 3,000 patients.

About Novasys Medical

Novasys Medical, Inc. is a privately held, venture-backed company which develops innovative therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a proprietary, non-surgical approach to the treatment of female stress urinary incontinence (SUI).

For more information, please visit www.novasysmedical.com or call (510) 226-4060.


'/>"/>
SOURCE Novasys Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aetna Now Covers Novasys Medicals Renessa(R) Treatment for Incontinence in Women
2. Owensboro Medical Health System Announces Results of Its Modified Dutch Auction Tender Offer
3. HealthCare Partners of Nevada and Fremont Medical Center Join Forces
4. All Allied Health Schools Helps Medical Coding Students Prepare for New Health Care World
5. Growth in African Medical Imaging Markets: Frost & Sullivan Examines the Potential
6. President Obama Holds Roundtable Discussion on Health Reform at Children's National Medical Center
7. Can pen and paper help make electronic medical records better?
8. ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe
9. Wake Forest Baptist Medical Center Names Chadwick CFO
10. One Healthcare Solution and MedBeyond Partner to Provide Optimum Solution for EMR and Medical Billing
11. MultiNational Underwriters Is Now HCC Medical Insurance Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... New York, New York (PRWEB) , ... May 24, 2017 , ... ... and general vascular surgery in New York City. He is known for ... his broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a ... advancements in his field by attending numerous CE courses each year. His recent ...
(Date:5/24/2017)... ... 24, 2017 , ... If you are thinking of a visit to San Francisco , ... is the perfect time to visit. , Business Architecture Associates is pleased to offer 5 ... individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package for ...
(Date:5/24/2017)... Falls, Wisconsin (PRWEB) , ... May 24, 2017 ... ... leader in clean label food ingredient solutions for the food and beverage industry ... factor in food ingredient statements during the purchasing decision process. As a result, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology: